Parker Labs in Alliance for Ultrasound Probe Disinfectant
|
By MedImaging International staff writers Posted on 19 Jul 2022 |

Parker Laboratories Inc. (Fairfield, NJ, USA) and Tristel plc (Newmarket, UK) have entered into a commercial partnership in which Tristel will manufacture and distribute its high-level ultrasound probe disinfectants.
Tristel is a UK-based manufacturer of infection prevention products. Ultrasound probe disinfection is one of Tristel's most important areas of focus within the hospital infection prevention market, accounting for approximately 40% of the company's global revenues. Parker is a leading manufacturer in the US market for the conductive gels and sheaths that are used in all ultrasound procedures, with a nationwide distribution network.
Tristel has submitted its De Novo request for approval to the US FDA for Tristel Duo ULT, a high-level disinfectant foam that can be used on ultrasound probes used for intra-cavitary and skin surface diagnostic procedures. To Tristel’s knowledge, Tristel Duo ULT is the first disinfectant to make a De Novo request to the FDA, reflecting the novelty of the product. Duo ULT is widely used throughout Europe, the Middle East, Asia, and Australasia. During the company's current financial year, the product will have been used in over eight million disinfection procedures of ultrasound probes worldwide.
The FDA's De Novo review and approval process stipulates a 150-day decision timeframe. Additional data requests are commonplace, and the FDA website states that the average duration for review and approval is approximately 11 months. Tristel is also proceeding with the state registration of another version of Duo which has been approved by the US EPA for the disinfection of general medical surfaces. The company has received 24 state approvals and anticipates that all others will have been received by the end of 2022. Tristel will manufacture and distribute both Duo products via its commercial partnership with Parker.
"After five years of testing and data generation we are very pleased to have finally submitted our De Novo request for approval to the FDA. We have made an investment of GBP 2.8 million in the project which has all been expensed," said Paul Swinney, Chief Executive of Tristel plc. "The United States is the largest ultrasound market in the world and our competitors will be the same as those we compete with in all our other markets worldwide. To our knowledge no new high-level disinfectant has been approved by the FDA and introduced into the United States since 2011, other than variants of previously approved products. Duo ULT is recognized as a leading high-level disinfectant throughout the rest of the world, and our entry into the United States market will be a significant inflection point for the company."
Related Links:
Parker Laboratories Inc.
Tristel plc
Latest Industry News News
- GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026
- GE HealthCare Highlights AI-Supported Radiation Therapy Tools at ESTRO 2026
- Nuclear Medicine Set for Continued Growth Driven by Demand for Precision Diagnostics
- GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
- Patient-Specific 3D-Printed Phantoms Transform CT Imaging
- Siemens and Sectra Collaborate on Enhancing Radiology Workflows
- Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy
- Mindray Partners with TeleRay to Streamline Ultrasound Delivery
- Philips and Medtronic Partner on Stroke Care
- Siemens and Medtronic Enter into Global Partnership for Advancing Spine Care Imaging Technologies
- RSNA 2024 Technical Exhibits to Showcase Latest Advances in Radiology
- Bracco Collaborates with Arrayus on Microbubble-Assisted Focused Ultrasound Therapy for Pancreatic Cancer
- Innovative Collaboration to Enhance Ischemic Stroke Detection and Elevate Standards in Diagnostic Imaging
- RSNA 2024 Registration Opens
- Microsoft collaborates with Leading Academic Medical Systems to Advance AI in Medical Imaging
- GE HealthCare Acquires Intelligent Ultrasound Group’s Clinical Artificial Intelligence Business
Channels
Radiography
view channel
AI Tool Predicts Five-Year Breast Cancer Risk from Mammograms
Breast cancer risk assessment during routine screening is difficult because many women who develop the disease have no known genetic mutations or family history. Static risk tools provide limited discrimination... Read more
AI Mammography Tools Detect Early Breast Cancer Signs Years Before Diagnosis
Breast cancer screening aims to detect tumors before symptoms develop, but subtle mammographic changes can appear years before diagnosis and may be missed during routine reads. Delayed detection can lead... Read moreMRI
view channel
Cardiac MRI Detects Hidden Heart Dysfunction After Heart Attack
Myocardial infarction often leaves patients with persistent ventricular dysfunction that can progress without obvious signs. Detecting early decline remains difficult because standard measures may miss... Read more
AI Tool Reveals Cortical Lesions on Standard MRI in Multiple Sclerosis
Multiple sclerosis (MS) causes immune-mediated damage in the brain that leads to disability and cognitive decline. Clinicians have long recognized that lesions in the brain’s gray matter, or cortex, are... Read moreUltrasound
view channel
Simple 2D Ultrasound Tool Accurately Estimates Placental Volume
Stillbirth remains a major cause of perinatal loss, with about 21,000 cases annually in the United States. Although placental abnormalities are linked to adverse pregnancy outcomes, routine monitoring... Read more
Portable 3D Ultrasound System Enables Reproducible Breast Cancer Monitoring
Breast cancer can develop between annual mammograms, and these interval cancers account for 20% to 30% of cases and tend to be more aggressive. The challenge is pronounced in people with dense breast tissue.... Read moreNuclear Medicine
view channel
Radiotherapy Professionals Embrace AI as a Clinical Support Tool
Radiotherapy planning requires precise identification of organs at risk near a tumor, but manual contouring is repetitive and time-consuming, often delaying plan completion and straining specialist capacity.... Read more
Second PSMA PET Identifies Disease in More Than Half of Negative Cases
Biochemical recurrence of prostate cancer after prostatectomy or radiation can be difficult to localize when imaging is negative. Uncertain disease sites may delay salvage therapy and expose patients to... Read moreGeneral/Advanced Imaging
view channel
Virtual Staining Technique Creates Histology Images from CT Data
Pulmonary hypertension, a disorder marked by pathological remodeling of the pulmonary vessels, often requires detailed histologic assessment. Yet routine pathology remains anchored in labor‑intensive,... Read more
CT-Derived Biomarker Predicts Outcomes in Gastric Cancer
Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more
AI Tool Enhances Response Assessment and Survival Prediction in Pleural Mesothelioma
Pleural mesothelioma, a cancer that grows as a thin, irregular layer along the lung wall, is difficult to measure on imaging. Clinicians rely on diameter-based Response Evaluation Criteria in Solid Tumors... Read moreImaging IT
view channel
Ambient AI Reporting Platform Streamlines Radiology Reporting
Radiology departments face growing imaging volumes and staffing shortages, creating reporting bottlenecks and pressure to maintain turnaround times. Conventional dictation tools document findings after... Read more
Interactive AI Tool Supports Explainable Lung Nodule Assessment
Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more







